Longitudinal Effectiveness and Laboratory Safety Profile of Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World Study
Pharmaceutics · 13.11.2026 · 18 (11) · 1473
DOI: 10.3390/pharmaceutics18111473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 13.11.2026. Verfasst von Carolina Montero-Vílchez und 4 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background/Objectives: Janus kinase inhibitors (JAKis) are effective treatments for moderate-to-severe atopic dermatitis (AD), although longitudinal real-world data on their laboratory safety profile remain limited and there is scarce information regarding whether laboratory changes differ according to JAKi use. So, the main objective of this study was to evaluate longitudinal laboratory changes in patients with AD treated with JAKis in routine clinical practice and to evaluate these changes across different types of JAKis.
Methods
We conducted a retrospective observational study including patients with moderate-to-severe AD who initiated treatment with abrocitinib, upadacitinib, or baricitinib. Demographic, clinical, laboratory, and patient-reported outcome data were collected at baseline and after 4, 12–16, 24–32, and 48–52 weeks. Longitudinal changes were analyzed using REML mixed-effects models with categorical visit and a patient-specific random intercept, using logarithmic transformations for skewed laboratory parameters.
Results
Forty-three patients were included. EASI decreased from 21.18 ± 8.82 at baseline to 6.06 ± 8.27 at week 4 and 7.85 ± 8.63 at weeks 48–52, while pruritus NRS decreased from 7.15 ± 2.48 to 2.23 ± 2.78 and 4.34 ± 3.28, respectively (p < 0.001). At weeks 24–32, total cholesterol (+29.26), LDL cholesterol (+16.09), HDL cholesterol (+6.57), and MCV (+2.12) increased significantly, whereas CRP (−2.87), leukocyte (−1.07), and neutrophil counts (−1.07) decreased significantly. Mean creatinine changes were small. No significant longitudinal changes were observed in AST, ALT, triglycerides or hemoglobin. Few between-treatment differences were identified. No MACE, VTE or changes in lipid-lowering treatment were documented during recorded follow-up.
Conclusions
JAKis provided substantial clinical benefit with a favorable longitudinal laboratory safety profile. Laboratory abnormalities were generally mild and consistent with the known safety profile of this class.
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Montero-Vílchez, C., Ruiz-Jiménez, A., Elosua-Gonzalez, M., Arias-Santiago, S., & Montero-Vílchez, T. (2026). Longitudinal Effectiveness and Laboratory Safety Profile of Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World Study. Pharmaceutics, 18(11), 1473. https://doi.org/10.3390/pharmaceutics18111473
Vancouver
Montero-Vílchez C, Ruiz-Jiménez A, Elosua-Gonzalez M, Arias-Santiago S, Montero-Vílchez T. Longitudinal Effectiveness and Laboratory Safety Profile of Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World Study. Pharmaceutics. 2026;18(11):1473. doi:10.3390/pharmaceutics18111473
BibTeX
@article{MonteroVlchez2026,
author = {Montero-Vílchez, Carolina and Ruiz-Jiménez, Alberto and Elosua-Gonzalez, Marta and Arias-Santiago, Salvador and Montero-Vílchez, Trinidad},
title = {Longitudinal Effectiveness and Laboratory Safety Profile of Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World Study},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1473},
doi = {10.3390/pharmaceutics18111473}
}
EUVIMED